<DOC>
	<DOCNO>NCT00030758</DOCNO>
	<brief_summary>RATIONALE : Colony-stimulating factor , filgrastim pegfilgrastim , may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . It yet know whether filgrastim pegfilgrastim effective standard treatment prevent neutropenia woman receive adjuvant chemotherapy breast cancer . PURPOSE : Randomized phase IV trial compare effectiveness filgrastim pegfilgrastim standard treatment prevent neutropenia woman receive chemotherapy undergo surgery breast cancer .</brief_summary>
	<brief_title>Filgrastim Pegfilgrastim Preventing Neutropenia Women Receiving Chemotherapy Following Surgery Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy filgrastim ( G-CSF ) pegfilgrastim secondary prophylaxis versus standard management first neutropenic event maintain dose-intensity adjuvant chemotherapy patient early breast cancer . - Determine proportion patient experience least one neutropenic event . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( 60 vs 60 ) participate center . Patients receive chemotherapy per local practice . After first neutropenic event , patient randomize 1 2 treatment arm . - Arm I : Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) 7 day begin 2 day final dose course adjuvant chemotherapy ( e.g. , begin day 3 course chemotherapy administer day 1 OR begin day 10 course chemotherapy administer day 1 8 ) OR single dose pegfilgrastim SC administer approximately 24 hour chemotherapy administer day 1 . - Arm II : Patients receive standard conservative management . Patients follow 10 year . PROJECTED ACCRUAL : A total 400 patient accrue study within 7 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer No locally advance metastatic breast cancer , include supraclavicular fossa metastasis Prior neutropenic event current chemotherapy regimen , define 1 following : Hospitalization due neutropenia Absolute neutrophil count â‰¤ 1.5 time upper limit normal consider sufficiently low require treatment delay dose reduction &gt; 15 % plan dose Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Other : No concurrent malignancy Considered suitable risk fitness status continue adjuvant chemotherapy PRIOR CONCURRENT THERAPY : Biologic therapy : No prior filgrastim ( GCSF ) pegfilgrastim Chemotherapy : See Disease Characteristics No prior chemotherapy current regimen Endocrine therapy : Prior tamoxifen allow Radiotherapy : Concurrent radiotherapy allow No concurrent sandwich/synchronous radiotherapy ( i.e. , administer break chemotherapy regimen ) Surgery : See Disease Characteristics Other : Concurrent enrollment license chemotherapy trial allow provide GCSF exclude ( e.g. , TACT TANGO trial ) Concurrent enrollment sequential arm SECRAB trial allow ( synchronous arm ineligible )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>neutropenia</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
</DOC>